Vion Pharmaceuticals, Inc.

Home

	ABOUT VION		PRODUCTS & PIPELINE		CLINICAL TRIALS		INVESTOR RELATIONS

WHAT'S NEW

Vion is Delisted from Nasdaq Stock Market

Vion Conference Call

Vion Reports 2008 Second Quarter and Six-Month Results • Quarterly Conference Call to be Held Thursday August 7 at 8:30 a.m.

Vion Poster Presentations at EHA Annual Meeting

Vion Announces Presentation of Data of Cloretazine® (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

Vion Announces Presentation of Data from Phase III Trial of Cloretazine® (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO® Annual Meeting

Vion Announces Initiation of Clinical Trial of Cloretazine® (VNP40101M) in Combination with Cytarabine

Vion Reports 2008 First Quarter Results

Vion Reports 2007 Fourth Quarter and Year-End Results

Vion Regains NASDAQ Listing Compliance

Vion to Implement a One-for-Ten Reverse Stock Split

Vion Pays Interest on 7.75% Convertible Senior Notes